{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:48:20Z","timestamp":1794624500685,"version":"4.9.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.71 per 100,000 population (malignant AAAIR=7.02 and non-malignant AAAIR=17.69). This overall rate was higher in females compared to males (27.62 versus 21.60 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.09 versus 22.95 per 100,000). The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.1% of all malignant tumors), and the most common non-malignant histopathology was meningioma (39.7% of all tumors and 55.4% of all non-malignant tumors). Glioblastoma was more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19\u00a0years), the incidence rate of all primary brain and other CNS tumors was 6.20 per 100,000 population. An estimated 93,470 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2022 (26,670 malignant and 66,806 non-malignant). There were 84,264 deaths attributed to malignant brain and other CNS tumors between 2015 and 2019. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 16,853 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, while for non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.<\/jats:p>","DOI":"10.1093\/neuonc\/noac202","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T05:10:26Z","timestamp":1664946626000},"page":"v1-v95","source":"Crossref","is-referenced-by-count":1568,"title":["CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019"],"prefix":"10.1093","volume":"24","author":[{"given":"Quinn T","family":"Ostrom","sequence":"first","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Duke Cancer Institute, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Price","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Neff","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Cioffi","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A","family":"Waite","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Kruchko","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill\u00a0S","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois , USA"},{"name":"Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute , Bethesda, Maryland , USA"},{"name":"Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"issue":"3","key":"2022100704471279800_CIT0001","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/neuonc\/noy006","article-title":"The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone","volume":"20","author":"Kruchko","year":"2018","journal-title":"Neuro Oncol"},{"key":"2022100704471279800_CIT0002","volume-title":"WHO Classification of Tumours of the Central Nervous System","author":"Louis","year":"2016"},{"issue":"4","key":"2022100704471279800_CIT0003","first-page":"317","article-title":"Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions","volume":"9","author":"Waite","year":"2022","journal-title":"Neurooncol. Pract"},{"key":"2022100704471279800_CIT0004","author":"Centers for Disease Control and Prevention (CDC)","year":"1999"},{"key":"2022100704471279800_CIT0005","year":"1992"},{"key":"2022100704471279800_CIT0006","year":"2002"},{"key":"2022100704471279800_CIT0007","author":"National Cancer Institute"},{"key":"2022100704471279800_CIT0008","volume-title":"National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database \u2013 2001-2018","author":"Centers for Disease Control and Prevention National Center for Health Statistics.","year":"2021"},{"key":"2022100704471279800_CIT0009","author":"Surveillance Research Program - National Cancer Institute.","year":"2019"},{"key":"2022100704471279800_CIT0010","volume-title":"International Classification of Diseases for Oncology, Third edition:","author":"Fritz","year":"2000"},{"key":"2022100704471279800_CIT0011","first-page":"134","article-title":"Consensus Conference on Brain Tumor Definition for registration. November 10, 2000","volume-title":"Neuro Oncol","author":"McCarthy","year":"2002"},{"key":"2022100704471279800_CIT0012","author":"Surveillance Epidemiology aERSP","year":"2017"},{"key":"2022100704471279800_CIT0013","volume-title":"International Incidence of Childhood Cancer, Volume III.","year":"2017"},{"issue":"7","key":"2022100704471279800_CIT0014","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/cncr.20910","article-title":"International Classification of Childhood Cancer, third edition","volume":"103","author":"Steliarova-Foucher","year":"2005","journal-title":"Cancer"},{"key":"2022100704471279800_CIT0015","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition:","author":"Swerdlow","year":"2007"},{"issue":"5","key":"2022100704471279800_CIT0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wisniewski","year":"2009","journal-title":"Nat. Methods"},{"issue":"1","key":"2022100704471279800_CIT0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11060-016-2217-7","article-title":"Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying)","volume":"130","author":"Ostrom","year":"2016","journal-title":"J. Neurooncol"},{"key":"2022100704471279800_CIT0018","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac113","article-title":"Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States","author":"Iorgulescu","year":"2022","journal-title":"Neuro Oncol"},{"key":"2022100704471279800_CIT0019","volume-title":"Tumours of the nervous system: World Health Organization classification of tumours","author":"Kleihues","year":"2000"},{"key":"2022100704471279800_CIT0020","volume-title":"WHO Classification of Tumours of the Central Nervous System","author":"Louis","year":"2007"},{"key":"2022100704471279800_CIT0021","author":"American Joint Committee on Cancer","year":"2020"},{"issue":"1","key":"2022100704471279800_CIT0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11060-015-1775-4","article-title":"Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011","volume":"123","author":"Lym","year":"2015","journal-title":"J. Neurooncol"},{"issue":"Suppl 4","key":"2022100704471279800_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"key":"2022100704471279800_CIT0024","article-title":"Histological groups","volume-title":"Cancer Incidence in Five Continents Volume XI","author":"Ferlay","year":"2019"},{"key":"2022100704471279800_CIT0025","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2019"},{"issue":"2","key":"2022100704471279800_CIT0026","first-page":"298","article-title":"Pilocytic astrocytomas: where do they belong in cancer reporting?","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"key":"2022100704471279800_CIT0027","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States 2014-2018","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"2022100704471279800_CIT0028","author":"Surveillance Epidemiology and End Results (SEER) Program.","year":"2021"},{"key":"2022100704471279800_CIT0029","year":"2008"},{"key":"2022100704471279800_CIT0030","article-title":"Data Comparability and Quality","author":"Bray","year":"2017","journal-title":"Cancer Incidence in Five Continents, Vol. XI"},{"key":"2022100704471279800_CIT0031","author":"R Core Team","year":"2021"},{"key":"2022100704471279800_CIT0032","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2022"},{"key":"2022100704471279800_CIT0033","author":"Luo","year":"2012"},{"key":"2022100704471279800_CIT0034","author":"Gohel","year":"2020"},{"key":"2022100704471279800_CIT0035","author":"Gohel","year":"2020"},{"issue":"10","key":"2022100704471279800_CIT0036","doi-asserted-by":"crossref","first-page":"24","DOI":"10.18637\/jss.v071.i10","article-title":"Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs","volume":"71","author":"Ho\u010devar","year":"2016","journal-title":"J. Stat. Softw"},{"issue":"43","key":"2022100704471279800_CIT0037","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw"},{"key":"2022100704471279800_CIT0038","author":"Sievert","year":"2020"},{"key":"2022100704471279800_CIT0039","author":"Xie","year":"2020"},{"key":"2022100704471279800_CIT0040","author":"Walker","year":"2020"},{"key":"2022100704471279800_CIT0041","author":"Kassambara","year":"2020"},{"issue":"1","key":"2022100704471279800_CIT0042","doi-asserted-by":"crossref","first-page":"439","DOI":"10.32614\/RJ-2018-009","article-title":"Simple Features for R: Standardized Support for Spatial Vector Data","volume":"10","author":"Pebesma","year":"2018","journal-title":"R J"},{"key":"2022100704471279800_CIT0043","author":"NAACCR Race and Ethnicity Work Group","year":"2012"},{"key":"2022100704471279800_CIT0044","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2020"},{"key":"2022100704471279800_CIT0045","first-page":"547","article-title":"Efficient interval estimation for age-adjusted cancer rates","volume-title":"Stat. Methods Med. Res","author":"Tiwari","year":"2006"},{"issue":"3","key":"2022100704471279800_CIT0046","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1541-0420.2006.00528.x","article-title":"Estimating average annual percent change for disease rates without assuming constant change","volume":"62","author":"Fay","year":"2006","journal-title":"Biometrics"},{"key":"2022100704471279800_CIT0047","year":"2022"},{"issue":"4","key":"2022100704471279800_CIT0048","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.27405","article-title":"Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence","volume":"118","author":"Zhu","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2022100704471279800_CIT0049","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med"},{"key":"2022100704471279800_CIT0050","first-page":"1290","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer","author":"Edwards","year":"2014"},{"issue":"6","key":"2022100704471279800_CIT0051","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7205\/MILMED-D-11-00434","article-title":"Cancer incidence among patients of the U.S. Veterans Affairs Health Care System","volume":"177","author":"Zullig","year":"2012","journal-title":"Mil. Med"},{"key":"2022100704471279800_CIT0052","first-page":"1537","article-title":"Impact of reporting delay and reporting error on cancer incidence rates and trends","volume-title":"J. Natl. Cancer Inst","author":"Clegg","year":"2002"},{"issue":"469","key":"2022100704471279800_CIT0053","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1198\/016214504000001899","article-title":"Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data","volume":"100","author":"Midthune","year":"2005","journal-title":"J. Am. Stat. Assoc"},{"key":"2022100704471279800_CIT0054","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2020"},{"issue":"4","key":"2022100704471279800_CIT0055","first-page":"187","article-title":"Are Benign and Borderline Brain Tumors Underreported?","volume":"43","author":"Li","year":"2016","journal-title":"J. Registry. Manag"},{"key":"2022100704471279800_CIT0056","volume-title":"Report of the Second Workshop on Age Adjustment","author":"Anderson","year":"1998"},{"issue":"3","key":"2022100704471279800_CIT0057","first-page":"1","article-title":"Age standardization of death rates: implementation of the year 2000 standard","volume":"47","author":"Anderson","year":"1998","journal-title":"Natl. Vital Stat. Rep"},{"key":"2022100704471279800_CIT0058","author":"L.","year":"2018"},{"key":"2022100704471279800_CIT0059","volume-title":"The 2007 Multiple Primary and Histology Coding Rules","author":"Johnson","year":"2007"},{"issue":"1","key":"2022100704471279800_CIT0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J.\u00a0Clin"},{"issue":"7","key":"2022100704471279800_CIT0061","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrclinonc.2016.204","article-title":"Advances in the molecular genetics of gliomas - implications for classification and therapy","volume":"14","author":"Reifenberger","year":"2017","journal-title":"Nat. Rev. Clin. Oncol"},{"issue":"19","key":"2022100704471279800_CIT0062","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/jnci\/90.19.1473","article-title":"Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas","volume":"90","author":"Cairncross","year":"1998","journal-title":"J. Natl. Cancer Inst"},{"issue":"3","key":"2022100704471279800_CIT0063","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J. Clin. Oncol"},{"issue":"3","key":"2022100704471279800_CIT0064","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-015-1845-7","article-title":"Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131","volume":"124","author":"Vogelbaum","year":"2015","journal-title":"J. Neurooncol"},{"issue":"3","key":"2022100704471279800_CIT0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van\u00a0den\u00a0Bent","year":"2013","journal-title":"J. Clin. Oncol"},{"issue":"26","key":"2022100704471279800_CIT0066","first-page":"2499","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors. New Engl","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"J. Med"},{"issue":"8","key":"2022100704471279800_CIT0067","first-page":"765","article-title":"IDH1 and IDH2 mutations in gliomas. New Engl","volume":"360","author":"Yan","year":"2009","journal-title":"J. Med"},{"issue":"26","key":"2022100704471279800_CIT0068","first-page":"2481","article-title":"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New Engl","volume":"372","author":"The Cancer Genome Atlas Research Network","year":"2015","journal-title":"J. Med"},{"issue":"3","key":"2022100704471279800_CIT0069","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"issue":"10","key":"2022100704471279800_CIT0070","first-page":"997","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl","volume":"352","author":"Hegi","year":"2005","journal-title":"J. Med"},{"issue":"25","key":"2022100704471279800_CIT0071","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J. Clin. Oncol"},{"issue":"26","key":"2022100704471279800_CIT0072","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp","year":"2007","journal-title":"J. Clin. Oncol"},{"issue":"10","key":"2022100704471279800_CIT0073","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3811","article-title":"Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma","volume":"14","author":"Jones","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"2022100704471279800_CIT0074","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat. Genet"},{"issue":"4","key":"2022100704471279800_CIT0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"2022100704471279800_CIT0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-015-0269-0","article-title":"Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics","volume":"4","author":"Hoffman","year":"2016","journal-title":"Acta Neuropathol. Commun"},{"issue":"4","key":"2022100704471279800_CIT0077","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pbc.24060","article-title":"Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma","volume":"58","author":"Grill","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"2022100704471279800_CIT0078","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fonc.2017.00057","article-title":"Genomic Insights into Diffuse Intrinsic Pontine Glioma","volume":"7","author":"Lapin","year":"2017","journal-title":"Front. Oncol"},{"issue":"4","key":"2022100704471279800_CIT0079","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00401-012-0958-8","article-title":"Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group\u00a03, and Group\u00a04 medulloblastomas","volume":"123","author":"Kool","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"7","key":"2022100704471279800_CIT0080","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/ern.12.66","article-title":"Molecular subgroups of medulloblastoma","volume":"12","author":"Northcott","year":"2012","journal-title":"Expert Rev. Neurother"},{"issue":"12","key":"2022100704471279800_CIT0081","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nrc3410","article-title":"Medulloblastomics: the end of the beginning","volume":"12","author":"Northcott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7663","key":"2022100704471279800_CIT0082","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"key":"2022100704471279800_CIT0083","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy002","article-title":"Females have the survival advantage in glioblastoma","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9","key":"2022100704471279800_CIT0084","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"2022100704471279800_CIT0085","first-page":"451","article-title":"Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma","volume":"6","author":"Gittleman","year":"2019","journal-title":"Neurooncol. Pract"},{"key":"2022100704471279800_CIT0086","first-page":"198","article-title":"Evaluation of North American Association of Central Cancer Registries\u2019 (NAACCR) data for use in population-based cancer survival studies. J. Natl. Cancer Inst. Monographs","author":"Weir","year":"2014"},{"issue":"2","key":"2022100704471279800_CIT0087","first-page":"65","article-title":"Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008","volume":"41","author":"Wilson","year":"2014","journal-title":"J. Registry. Manag"},{"issue":"3","key":"2022100704471279800_CIT0088","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","article-title":"The new WHO classification of brain tumours","volume":"3","author":"Kleihues","year":"1993","journal-title":"Brain Pathol"},{"key":"2022100704471279800_CIT0089","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"2022100704471279800_CIT0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00401-010-0725-7","article-title":"Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician\u2019s perspective","volume":"120","author":"van\u00a0den\u00a0Bent","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"10","key":"2022100704471279800_CIT0091","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X","article-title":"Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study","volume":"88","author":"Aldape","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"2022100704471279800_CIT0092","first-page":"330","article-title":"Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors","volume":"6","author":"Kruchko","year":"2019","journal-title":"Neurooncol. Pract"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/Supplement_5\/v1\/46359484\/noac202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/Supplement_5\/v1\/46359484\/noac202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T01:04:47Z","timestamp":1665104687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/Supplement_5\/v1\/6742201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":92,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac202","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,5]]},"published":{"date-parts":[[2022,10,5]]}}}